Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 16,122 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Disorder Clear all
Withdrawn Phase 1 Interventional

Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS II

NCT05238324
View directory record Official record
Conditions
Mucopolysaccharidosis II
Interventions
Genetic HMI-203
Biological
Lead sponsor
Homology Medicines, Inc
Industry
Eligibility
18 Years to 45 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
5
States / cities
Oakland, California • New Haven, Connecticut • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 30, 2026, 10:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Sleep Intervention to Improve Outcomes Among Women at High Risk of Breast Cancer

NCT02613923
View directory record Official record
Conditions
Breast Cancer, Sleep
Interventions
GO! To Sleep, Sleep information, Blood Draw, Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), SF-12 quality of life survey
Behavioral · Procedure · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Oct 30, 2026, 10:30 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use

NCT00535769
View directory record Official record
Conditions
Skin Cancer
Interventions
Electronic + no text message, Electronic monitor + text messages
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2012 · Synced Oct 30, 2026, 10:30 PM EDT
Completed Phase 2 Interventional Results available

Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne

NCT02575950
View directory record Official record
Conditions
Acne Vulgaris
Interventions
LEO43204, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 35 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lomita, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 30, 2026, 10:30 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2, Muti-Center Study of Repeat Dosing of Squaric Acid Dibutyl Ester in Subjects With Herpes Labialis

NCT03521479
View directory record Official record
Conditions
Herpes Labialis, HSV
Interventions
Squaric Acid Dibutyl Ester
Drug
Lead sponsor
Squarex, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Doral, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 6, 2021 · Synced Oct 30, 2026, 10:30 PM EDT
Completed Phase 1 Interventional

Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer

NCT01624441
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Interventions
Dinaciclib, Epirubicin Hydrochloride, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2018 · Synced Oct 30, 2026, 10:30 PM EDT
Withdrawn No phase listed Observational

A Pilot Study to Explore the Role of Gut Flora in Psoriasis

NCT04099979
View directory record Official record
Conditions
Psoriasis, Psoriasis Vulgaris, Psoriasis Universalis, Psoriasis Face, Psoriasis Nail, Psoriatic Plaque, Psoriasis Diffusa, Psoriasis Punctata, Psoriasis Palmaris, Psoriasis Circinata, Psoriasis Annularis, Psoriasis Genital, Psoriasis of Scalp, Psoriasis Geographica
Interventions
No Intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 30, 2026, 10:30 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Exergaming Intervention and Breast Cancer Biomarkers in Black Women

NCT02152462
View directory record Official record
Conditions
Breast Cancer, Obesity
Interventions
Exergaming
Other
Lead sponsor
Georgetown University
Other
Eligibility
40 Years to 59 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 30, 2026, 10:30 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2

NCT03017846
View directory record Official record
Conditions
Molluscum Contagiosum
Interventions
Cantharidin
Drug
Lead sponsor
Steven R Cohen
Other
Eligibility
2 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 30, 2026, 10:30 PM EDT
Completed Not applicable Interventional

Helping Women Stay Up-To-Date With Cancer Screening By Using a Prevention Care Manager or Usual Care

NCT00477646
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer, Colorectal Cancer
Interventions
Prevention Care Management
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
50 Years to 64 Years · Female only
Enrollment
2,241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2011 · Synced Oct 30, 2026, 10:30 PM EDT
Recruiting Not applicable Interventional

Lean Beef as Part of a Healthy Meal Plan in Adolescents With Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS)

NCT07780188
View directory record Official record
Conditions
PCOS (Polycystic Ovary Syndrome), Obese Adolescents, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities, Overweight Adolescents, Irregular Menstrual Cycle, Irregular Menstrual Cycles, Hirsutism, Hyperandrogenism
Interventions
Beef+
Other
Lead sponsor
Texas A&M University
Other
Eligibility
11 Years to 17 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 30, 2026, 10:30 PM EDT
Completed Phase 2 Interventional Results available

Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer

NCT00284180
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer
Interventions
Vinflunine, Trastuzumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
10
States / cities
Anniston, Alabama • Fort Myers, Florida • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2013 · Synced Oct 30, 2026, 10:30 PM EDT
Not listed Not applicable Interventional

VR for Surgical Prehabilitation and Rehabilitation

NCT06334380
View directory record Official record
Conditions
Breast Cancer, Frailty, Surgery
Interventions
Virtual Reality Modules Only, Virtual Reality Modules + Live Physical Therapist Support
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 30, 2026, 10:30 PM EDT
Completed Phase 2 Interventional Results available

Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD

NCT01808196
View directory record Official record
Conditions
Eosinophilic Esophagitis, Connective Tissue Disorders
Interventions
Losartan Potassium
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 30, 2026, 10:30 PM EDT
Completed Phase 4 Interventional

Evaluation of the Clinical Effectiveness of a Collagen-ORC Antimicrobial Matrix in Full-Thickness, Neuropathic Diabetic Foot Ulcers

NCT00235196
View directory record Official record
Conditions
Foot Ulcer
Interventions
Collagen ORC Antimicrobial Matrix (CAM)
Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Timeline
2004 – 2005
U.S. locations
3
States / cities
Fort Lauderdale, Florida • South Miami, Florida • Warren, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2006 · Synced Oct 30, 2026, 10:30 PM EDT
Recruiting Not applicable Interventional

Evaluation of the Efficacy of Hyalomatrix® in the Healing of Chronic Venous Leg Ulcers

NCT07335861
View directory record Official record
Conditions
Venous Leg Ulcer, Chronic Wounds
Interventions
Hyalomatrix, Standard of Care
Device · Other
Lead sponsor
NuScience Medical Biologics, LLC
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Alexandria, Louisiana • Pineville, Louisiana • Vidalia, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 30, 2026, 10:30 PM EDT
Completed Early Phase 1 Interventional

Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer

NCT00640861
View directory record Official record
Conditions
Breast Cancer
Interventions
CpG oligodeoxynucleotide, HER-2/neu peptide vaccine, MUC-1 peptide vaccine, incomplete Freund's adjuvant, sargramostim, immunoenzyme technique, immunologic technique
Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 30, 2026, 10:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Registry for the Atopic Dermatitis Research Network

NCT01494142
View directory record Official record
Conditions
Atopic Dermatitis, Eczema Herpeticum
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Months to 80 Years
Enrollment
3,387 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
9
States / cities
Los Angeles, California • Denver, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 30, 2026, 10:30 PM EDT
Completed Phase 2 Interventional Results available

ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate

NCT02387762
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
acalabrutinib, Placebo
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
17
States / cities
Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 30, 2026, 10:30 PM EDT
Withdrawn No phase listed Observational

Defining Musical Toxicity and Its Effect on Patient Well-being

NCT06494046
View directory record Official record
Conditions
Breast Carcinoma, Esophageal Carcinoma, Head and Neck Carcinoma, Lung Carcinoma, Malignant Brain Neoplasm, Malignant Solid Neoplasm
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 30, 2026, 10:30 PM EDT
Terminated No phase listed Observational

Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma

NCT00996827
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years to 95 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 18, 2015 · Synced Oct 30, 2026, 10:30 PM EDT
Completed Phase 2 Interventional Results available

Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer

NCT03206203
View directory record Official record
Conditions
Triple Negative Breast Cancer, Stage IV Breast Cancer, HER2 Negative, Invasive Breast Cancer
Interventions
Atezolizumab, Carboplatin, Laboratory Biomarker, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Indianapolis, Indiana • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 30, 2026, 10:30 PM EDT
Completed Phase 1 Interventional

Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis

NCT00001761
View directory record Official record
Conditions
Vasculitis, Wegener's Granulomatosis
Interventions
Interleukin-10
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 30, 2026, 10:30 PM EDT
Recruiting Phase 1 Interventional

Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer

NCT07652242
View directory record Official record
Conditions
Triple Negative Breast Cancer (TNBC)
Interventions
ITI-5000 mRNA Vaccine, Pembrolizumab, Olaparib, Capecitabine, ITI-5000 MTD (Maximum Tolerated Dose)
Biological · Drug
Lead sponsor
Immunomic Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Grand Rapids, Michigan • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 30, 2026, 10:30 PM EDT